Behcet's syndrome and treatment Archives

Abstract Number: 2968 • ACR/ARHP Annual Meeting 2016
Efficacy of Anti-TNF Alpha in Severe and Refractory Cardiovascular Involvement of Behcet’s Disease: A Multicenter Observational Study of 18 Patients
Anne-Claire Desbois¹, Olga Addimanda², Marc Lambert³, Eric Hachulla³, F. Ackermann⁴, Benjamin subran⁵, Arnaud Hot⁶, Francois Maurier⁷, christelle mausservey⁸, Fanny Bernard⁹, tristan mirault¹⁰, Fleur Cohen¹¹, Laurent Perard¹², Gaelle Leroux¹³, nicolas champtiaux¹⁴, Patrice Cacoub¹⁵ and David Saadoun¹⁶, ¹Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ²Rheumatology Unit, Istituto Ortopedico Rizzoli, Bologna, Italy, ³CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ⁴internal medicine, Hopital Foch, Suresnes, France, ⁵hopital foch, suresnes, France, ⁶Internal Medicine, Hopital Edouard Herriot, Lyon, France, ⁷Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁸CH Chalon sur saone, Chalon sur saone, France, ⁹CHU Marseille, marseille, France, ¹⁰HEGP, paris, France, ¹¹Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ¹²Hôpital Edouard Herriot, Lyon, France, ¹³Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ¹⁴Pitié SAlpétrière, paris, France, ¹⁵Department of Internal Medicine, Pitié-Salpêtrière Hospital, Paris, France, ¹⁶Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France
Background/Purpose: In Behçet's disease (BD), vascular complications affect more than 30% patients. Cardiovascular involvement is the main cause of death, especially for pulmonary or aortic…
Abstract Number: 761 • ACR/ARHP Annual Meeting 2013
Apremilast For The Treatment Of Behçet’s Syndrome: A Phase II Randomized, Placebo-Controlled, Double-Blind Study
Gulen Hatemi¹, Melike Melikoglu², Recep Tunc³, Cengiz Korkmaz⁴, Banu Turgut Ozturk⁵, Cem Mat⁶, Peter A. Merkel⁷, Kenneth Calamia⁸, Ziqi Liu⁹, Lilia Pineda⁹, Randall M. Stevens⁹, Hasan Yazici² and Yusuf Yazici¹⁰, ¹Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³Necmettin Erbakan University, Meram Medical Faculty,Division of Rheumatology, Konya, Turkey, ⁴Eskisehir Osmangazi University, Eskisehir, Turkey, ⁵Selçuk University, Konya, Turkey, ⁶Istanbul University, Cerrahpasa Medical Faculty, Dermatology, Istanbul, Turkey, ⁷Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ⁸Mayo Clinic, Jacksonville, FL, ⁹Celgene Corporation, Warren, NJ, ¹⁰Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Apremilast for the Treatment of Behçet's Syndrome: A Phase II Randomized, Placebo-Controlled, Double-Blind StudyBackground/Purpose: Mucocutaneous manifestations of Behçet's syndrome (BS) can be resistant to conventional…

Abstracts tagged "Behcet’s syndrome and treatment"

Efficacy of Anti-TNF Alpha in Severe and Refractory Cardiovascular Involvement of Behcet’s Disease: A Multicenter Observational Study of 18 Patients

Apremilast For The Treatment Of Behçet’s Syndrome: A Phase II Randomized, Placebo-Controlled, Double-Blind Study